Journal: Archives of Virology

Article Title: Therapeutic effect of an anti-human-TNF-alpha antibody and itraconazole on feline infectious peritonitis

doi: 10.1007/s00705-020-04605-7

Figure Lengend Snippet: Changes in plasma vascular endothelial growth factor (VEGF) concentration in cats. †: The cat was euthanized because its clinical condition had reached the humane endpoint

Article Snippet: Plasma concentrations of VEGF were determined using a human VEGF ELISA Kit (R & D Systems, Minneapolis, MN, USA), according to the manufacturer’s protocol.

Techniques: Clinical Proteomics, Concentration Assay

Journal: Neurology® Neuroimmunology & Neuroinflammation

Article Title: The Aryl Hydrocarbon Receptor–Dependent TGF-α/VEGF-B Ratio Correlates With Disease Subtype and Prognosis in Multiple Sclerosis

doi: 10.1212/NXI.0000000000001043

Figure Lengend Snippet: TGF-α (A, B) and VEGF-B (C, D) levels as well as AHR agonistic activity (G, H) in serum samples of patients with RRMS in remission (n = 98), SPMS (n = 44), PPMS (n = 36), and their respective controls (A, C, E, G: n = 43; B, D, F, H: n = 16) were assessed. TGF-α and VEGF-B levels were measured in pg/mL using a human TGF-α or VEGF-B ELISA. TGF-α/VEGF-B ratio (E, F) was determined by dividing TGF-α levels by VEGF-B levels. An AHR ligand–sensitive luciferase assay was used. Relative activity was calculated by dividing firefly luciferase activity (pGud-Luc) by Renilla luciferase activity (pTK-Renilla). Values are means of duplicate measurements. Lines represent median and interquartile range. Significance levels were derived using nonparametric tests (Mann-Whitney test and Kruskal-Wallis test with the Dunn multiple comparison test correcting for multiple comparisons). **** p < 0.0001, *** p < 0.001, ** p < 0.001, * p < 0.01, and ns = nonsignificant. AHR = aryl hydrocarbon receptor; MS = multiple sclerosis; PPMS = primary progressive MS; RRMS = relapsing-remitting MS; SPMS = secondary progressive MS; TGF-α = transforming growth factor alpha; VEGF-B = vascular endothelial growth factor B.

Article Snippet: Commercial TGF-α ELISA Kit (EHTGF-Α, Thermo Scientific) and VEGF-B ELISA Kit (CSB-E04758h, CUSABIO) were used for the quantitative determination of TGF-α and VEGF-B levels.

Techniques: Activity Assay, Enzyme-linked Immunosorbent Assay, Luciferase, Derivative Assay, MANN-WHITNEY, Comparison

Journal: Neurology® Neuroimmunology & Neuroinflammation

Article Title: The Aryl Hydrocarbon Receptor–Dependent TGF-α/VEGF-B Ratio Correlates With Disease Subtype and Prognosis in Multiple Sclerosis

doi: 10.1212/NXI.0000000000001043

Figure Lengend Snippet: TGF-α (A) and VEGF-B (B) levels as well as AHR agonistic activity (D) were assessed in serum samples of patients with RRMS in remission (n = 98), RRMS during relapse (n = 54), and controls (n = 44). TGF-α and VEGF-B levels were measured in pg/mL using a human TGF-α or VEGF-B ELISA. TGF-α/VEGF-B ratio (C) was determined by dividing TGF-α levels by VEGF-B levels. An AHR ligand–sensitive luciferase assay was used. Relative activity was calculated by dividing firefly luciferase activity (pGud-Luc) by Renilla luciferase activity (pTK-Renilla). Values are means of duplicate measurements. Lines represent median and interquartile range. Significance levels were derived using the nonparametric Kruskal-Wallis test with the Dunn multiple comparison test correcting for multiple comparisons. **** p < 0.0001, *** p < 0.001, ** p < 0.001, * p < 0.01, and ns = nonsignificant. AHR = aryl hydrocarbon receptor; RRMS = relapsing-remitting multiple sclerosis; TGF-α = transforming growth factor alpha; VEGF-B = vascular endothelial growth factor B.

Article Snippet: Commercial TGF-α ELISA Kit (EHTGF-Α, Thermo Scientific) and VEGF-B ELISA Kit (CSB-E04758h, CUSABIO) were used for the quantitative determination of TGF-α and VEGF-B levels.

Techniques: Activity Assay, Enzyme-linked Immunosorbent Assay, Luciferase, Derivative Assay, Comparison

Journal: Neurology® Neuroimmunology & Neuroinflammation

Article Title: The Aryl Hydrocarbon Receptor–Dependent TGF-α/VEGF-B Ratio Correlates With Disease Subtype and Prognosis in Multiple Sclerosis

doi: 10.1212/NXI.0000000000001043

Figure Lengend Snippet: TGF-α (A) and VEGF-B (B) levels as well as AHR agonistic activity (D) were assessed in serum samples of patients with RRMS in remission (n = 98), CIS (n = 20), and controls (n = 44). TGF-α and VEGF-B levels were measured in pg/mL using a human TGF-α or VEGF-B ELISA. TGF-α/VEGF-B ratio (C) was determined by dividing TGF-α levels by VEGF-B levels. An AHR ligand–sensitive luciferase assay was used. Relative activity was calculated by dividing firefly luciferase activity (pGud-Luc) by Renilla luciferase activity (pTK-Renilla). Values are means of duplicate measurements. Lines represent median and interquartile range. Significance levels were derived using the nonparametric Kruskal-Wallis test with the Dunn multiple comparison test correcting for multiple comparisons. **** p < 0.0001, *** p < 0.001, ** p < 0.001, * p < 0.01, and ns = nonsignificant. AHR = aryl hydrocarbon receptor; CIS = clinically isolated syndrome; RRMS = relapsing-remitting multiple sclerosis; TGF-α = transforming growth factor alpha; VEGF-B = vascular endothelial growth factor B.

Article Snippet: Commercial TGF-α ELISA Kit (EHTGF-Α, Thermo Scientific) and VEGF-B ELISA Kit (CSB-E04758h, CUSABIO) were used for the quantitative determination of TGF-α and VEGF-B levels.

Techniques: Activity Assay, Enzyme-linked Immunosorbent Assay, Luciferase, Derivative Assay, Comparison, Isolation

Journal: Neurology® Neuroimmunology & Neuroinflammation

Article Title: The Aryl Hydrocarbon Receptor–Dependent TGF-α/VEGF-B Ratio Correlates With Disease Subtype and Prognosis in Multiple Sclerosis

doi: 10.1212/NXI.0000000000001043

Figure Lengend Snippet: TGF-α/VEGF-B ratio (A) and AHR agonistic activity (B) in serum samples of patients with RRMS in remission (n = 98) were assessed. TGF-α and VEGF-B levels were measured in pg/mL using a human TGF-α or VEGF-B ELISA. TGF-α/VEGF-B ratio was determined by dividing TGF-α levels by VEGF-B levels. An AHR ligand–sensitive luciferase assay was used. Relative activity was calculated by dividing firefly luciferase activity (pGud-Luc) by Renilla luciferase activity (pTK-Renilla). Values are presented as means of duplicate measurements. Line shows linear regression of the TGF-α/VEGF-B ratio or AHR agonistic activity and patients' EDSS. Significance levels were derived using Spearman correlation analysis (A: Spearman r = −0.2427; R 2 = 0.059; B: Spearman r = −0.2433; R 2 = 0.059). AHR = aryl hydrocarbon receptor; EDSS = Expanded Disability Status Scale; RRMS = relapsing-remitting multiple sclerosis; TGF-α = transforming growth factor alpha; VEGF-B = vascular endothelial growth factor B.

Article Snippet: Commercial TGF-α ELISA Kit (EHTGF-Α, Thermo Scientific) and VEGF-B ELISA Kit (CSB-E04758h, CUSABIO) were used for the quantitative determination of TGF-α and VEGF-B levels.

Techniques: Activity Assay, Enzyme-linked Immunosorbent Assay, Luciferase, Derivative Assay

Journal: Molecular Therapy. Nucleic Acids

Article Title: Nanoparticle delivery of VEGF-B mRNA promotes T cell infiltration within tumor and triggers robust antitumor immunity

doi: 10.1016/j.omtn.2025.102620

Figure Lengend Snippet: Characterization of VEGF-B mRNA modifications and mRNA-LNPs (A and B) IP-western blot analysis of VEGF-B protein expression in HEK293T and B16F10 cells after transfection of VEGF-B mRNA with different modifications and tailing method. Non, non-modified; m1Ψ, m1Ψ-modified and EPAP tailing; Ψ1, Ψ-modified and EPAP tailing; Ψ2, Ψ-modified and co-transcriptionally tailing. (C) Transmission electron microscopy observation of VEGF mRNA-LNP; scale bars, 200 μm. (D) Size distribution of VEGF mRNA-LNP and control mRNA-LNP detected by Malvern dynamic light scattering Zetasizer. (E) VEGF-B protein secretion levels in B16F10 cells transfected with VEGF-B mRNA-LNP, detected by ELISA. Cells in a six-well plate were transfected with 2 μg of the modified mRNA per well. Data are presented as the median ± standard error of the mean (SEM). Significance was determined with ordinary one-way ANOVA in (E). ∗∗∗∗ p < 0.0001.

Article Snippet: The concentration of VEGF-B protein was quantified through ELISA with the mouse VEGF-B ELISA kit (KOA0852, Rockland Immunochemicals Inc.), adhering strictly to the protocol provided by the manufacturer.

Techniques: Western Blot, Expressing, Transfection, Modification, Transmission Assay, Electron Microscopy, Control, Enzyme-linked Immunosorbent Assay

Journal: Discover Oncology

Article Title: The molecular mechanism of gemcitabine in inhibiting the HIF-1α/VEGFB/FGF2/FGFR1 signaling pathway for ovarian cancer treatment

doi: 10.1007/s12672-024-01723-5

Figure Lengend Snippet: Exploration of the Impact of GEM Treatment on Other Key Genes. A PPI network of genes interacting with HIF-1α among significant DEGs; B Correlation heatmap of genes interacting with HIF-1α; C Boxplots of expression levels of VEGF-B, PROX1, SOD2 (control-OVCAR3, n = 3, GEM-OVCAR3, n = 3); D – F Boxplots of expression levels of VEGF-B ( D ), PROX1 ( E ), SOD2 ( F ) in TCGA_GTEx-OV dataset, where * indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001 (TCGA_GTEx-OV dataset: Normal: n = 88, Tumor: n = 427); (G) PPI network of genes interacting with VEGF-B among significantly DEGs; (H) Boxplots of expression levels of FGF2 and FGFR1 (control-OVCAR3, n = 3, GEM-OVCAR3, n = 3)

Article Snippet: The commercial FGFR1 silencing lentivirus (sc-39840-V) was purchased from Santa Cruz Biotechnology (Shanghai) and titrated to 10 9 TU/mL.

Techniques: Expressing, Control

Journal: Discover Oncology

Article Title: The molecular mechanism of gemcitabine in inhibiting the HIF-1α/VEGFB/FGF2/FGFR1 signaling pathway for ovarian cancer treatment

doi: 10.1007/s12672-024-01723-5

Figure Lengend Snippet: Validation of the upstream–downstream relationships of HIF-1α, VEGF-B, and FGF2/FGFR1. A Overexpression of HIF-1α followed by qPCR A and Western blot analysis B to assess the expression levels of HIF-1α, VEGF-B, FGF2, and FGFR1; C Overexpression of VEGF-B followed by qPCR C and Western blot analysis D to evaluate the expression levels of HIF-1α, VEGF-B, FGF2, and FGFR1; E Overexpression of FGFR1 followed by qPCR E and Western blot analysis F to determine the expression levels of HIF-1α, VEGF-B, FGF2, and FGFR1. Cell experiments were conducted in triplicate. *P < 0.05, **P < 0.01, ***P < 0.001

Article Snippet: The commercial FGFR1 silencing lentivirus (sc-39840-V) was purchased from Santa Cruz Biotechnology (Shanghai) and titrated to 10 9 TU/mL.

Techniques: Biomarker Discovery, Over Expression, Western Blot, Expressing

Journal: Discover Oncology

Article Title: The molecular mechanism of gemcitabine in inhibiting the HIF-1α/VEGFB/FGF2/FGFR1 signaling pathway for ovarian cancer treatment

doi: 10.1007/s12672-024-01723-5

Figure Lengend Snippet: Exploring the molecular mechanisms of Dioscorea nipponica Makino extract on inhibiting the proliferation, migration, invasion capabilities, and angiogenesis of ovarian cancer cells. A , B qPCR and WB analysis of HIF-1α, VEGF-B, FGF2, and FGFR1 expression levels in ISsh-80, SK-OV-3, and SK-OV-3/GEM cells; C , D qPCR and WB analysis of HIF-1α, VEGF-B, FGF2, and FGFR1 expression levels in the control (SK-OV-3), GEM, oe-NC + GEM, oe-HIF-1α + GEM, and oe-HIF-1α + sh-FGFR1 + GEM groups; E CCK-8 assay measuring the differences in proliferation across groups; F Scratch assay measuring the differences in migration across groups; G Transwell assay measuring the differences in invasion across groups; H Angiogenesis assay measuring the formation of tubular structures across groups. All experiments were repeated three times. Cell experiments were repeated three times. **P < 0.01, ***P < 0.001

Article Snippet: The commercial FGFR1 silencing lentivirus (sc-39840-V) was purchased from Santa Cruz Biotechnology (Shanghai) and titrated to 10 9 TU/mL.

Techniques: Migration, Expressing, Control, CCK-8 Assay, Wound Healing Assay, Transwell Assay, Angiogenesis Assay